[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555176":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":45,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BTK inhibitor treated",null,"investigate the current situation of BTK inhibitor treatment for CLL\u002FSLL patients in China and the related influencing factors, including the efficacy and safety, the drug swith between different BTKis，the BTKi based timed limited therapy, etc",[13],"Drug: BTK inhibitor",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","BTK inhibitor","BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Huayuan Zhu, MD","CONTACT","025-58530260","huayuan.zhu@hotmail.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital","RECRUITING","Nanjin","Jiangsu","210029","China","CN",{"type":36,"coordinates":37},"Point",[38,39],121.74055,31.75772,{"lat":39,"lon":38},[42],{"name":43,"role":23,"phone":44,"phoneExt":10,"email":25},"Huayuan Zhu, PhD，MD","86 25 68306034",{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100555176","current-status-of-btki-treatment-for-cllsll-in-china-100555176",false,"NCT06508684","Current Status of BTKi Treatment for CLL\u002FSLL in China","Current Status and Influencing Factors of Chinese Patients With Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma Undergoing Treatment With Bruton's Tyrosine Kinase Inhibitors","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Patients with a confirmed diagnosis of CLL\u002FSLL;\n* Received BTK inhibitor treatment between February 2023 and February 2024.\n\nExclusion Criteria:\n\n* Patients with other types of lymphoma;\n* Cases deemed unsuitable for inclusion in this study by the investigators.","ALL","18 Years","80 Years",{"count":58,"type":59},1000,"ESTIMATED","OBSERVATIONAL","BTKi has become the standard treatment regimen for CLL\u002FSLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL\u002FSLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.",[63],"CLL\u002FSLL","2024-07-14",{"date":66,"type":67},"2024-07-18","ACTUAL",{"date":69,"type":67},"2024-07-13",{"date":71,"type":59},"2025-07-12",{"name":5,"class":6},1]